within Pharmacolibrary.Drugs.ATC.L;

model L01XX41
  extends Pharmacokinetic.Models.PK_3C(
    weight         = 70,
    F              = 1,
    Cl             = 4.133333333333333e-05,
    adminDuration  = 600,
    adminMass      = 1.4 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0673,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>L01XX41</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>3</td></tr></table><p>Eribulin is a microtubule dynamics inhibitor, used as an anticancer drug primarily for the treatment of metastatic breast cancer and liposarcoma. It is a synthetic analog of halichondrin B and is approved for clinical use in multiple countries.</p><h4>Pharmacokinetics</h4><p>Mean pharmacokinetic parameters in adult patients with advanced solid tumors, primarily female, following intravenous administration.</p><h4>References</h4><ol><li><p>Shimizu, T, et al., &amp; Yamamoto, N (2021). First-in-Human Phase 1 Study of MORAb-202, an Antibody-Drug Conjugate Comprising Farletuzumab Linked to Eribulin Mesylate, in Patients with Folate Receptor-α-Positive Advanced Solid Tumors. <i>Clinical cancer research : an official journal of the American Association for Cancer Research</i> 27(14) 3905–3915. DOI:<a href=&quot;https://doi.org/10.1158/1078-0432.CCR-20-4740&quot;>10.1158/1078-0432.CCR-20-4740</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33926914/&quot;>https://pubmed.ncbi.nlm.nih.gov/33926914</a></p></li><li><p>Devriese, LA, et al., &amp; Schellens, JH (2013). Eribulin mesylate pharmacokinetics in patients with solid tumors receiving repeated oral ketoconazole. <i>Investigational new drugs</i> 31(2) 381–389. DOI:<a href=&quot;https://doi.org/10.1007/s10637-012-9829-3&quot;>10.1007/s10637-012-9829-3</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/22555773/&quot;>https://pubmed.ncbi.nlm.nih.gov/22555773</a></p></li><li><p>Devriese, LA, et al., &amp; Schellens, JH (2013). Pharmacokinetics of eribulin mesylate in patients with solid tumours receiving repeated oral rifampicin. <i>British journal of clinical pharmacology</i> 75(2) 507–515. DOI:<a href=&quot;https://doi.org/10.1111/j.1365-2125.2012.04381.x&quot;>10.1111/j.1365-2125.2012.04381.x</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/22803519/&quot;>https://pubmed.ncbi.nlm.nih.gov/22803519</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end L01XX41;
